SLC5A2 and heart failure: These findings support the growing body of evidence advocating for the incorporation of SGLT2 inhibitors into the standard of care for HFrEF, emphasizing the need for further multicenter studies, longer follow-up periods, and comparative analyses among different SGLT2 inhibitors to refine treatment strategies and optimize patient outcomes in heart failure management.